Login to Your Account

More Positive Data for CF Drug VX-770; Vertex Eyes 2H11 NDA

By Staff Reports

Wednesday, March 30, 2011
A month after reporting positive data for cystic fibrosis (CF) candidate VX-770 in adult patients, Vertex Pharmaceuticals Inc. disclosed better-than-expected results in a separate study involving children ages 6 to 11, which should further bolster regulatory filings expected in the second half of this year.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription